Zydus Lifesciences’ stock saw a nearly 3% jump after the company announced that the US FDA completed a surveillance inspection at its API Manufacturing site in Ambernath, Maharashtra, from February 10 to 14, 2025. The inspection concluded with no observations, marking a positive outcome for the company.
In the exchange filing, the company shared, “We wish to inform that the USFDA conducted a surveillance inspection at the group’s API Manufacturing site situated at Ambernath in Maharashtra. The inspection was conducted from February 10th to 14th, 2025. The inspection concluded with NIL observations.”
Zydus Lifesciences shares opened at ₹904.30, reaching a high of ₹927.50 and a low of ₹892.00. The stock is currently trading between its 52-week high of ₹1,324.30 and 52-week low of ₹889.00. As of 11:04 AM, the shares were trading 2.75% higher at Rs 926.65.
Zydus Lifesciences Q3 FY25 Results
Zydus Lifesciences Limited reported impressive financial performance for the quarter ending December 31, 2024. The company achieved consolidated revenue of ₹5,269.1 crore, marking a 16.78% year-on-year increase from ₹4,505.2 crore in Q3 FY24.
Total expenses for the quarter were ₹4,142.5 crore, reflecting a 14.52% rise, primarily driven by higher operational and input costs. Profit before tax (PBT) surged 46.78%, reaching ₹1,044.6 crore, compared to ₹711.7 crore in the same period last year.
Net profit from continuing operations grew by 29.6% YoY to ₹1,023.8 crore, while the overall net profit, including exceptional items, rose by 33.3% to ₹1,023.5 crore. The company also recorded a significant forex gain of ₹183 crore, up from ₹21 crore in Q3 FY24, demonstrating effective currency management.
EBITDA climbed 25.85% year-on-year, totaling ₹1,387 crore, with an improved EBITDA margin of 26.3%, up from 24.5% in Q3 FY24.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
